Anthony G. Quinn - President & CEO, Director at Spyre Therapeutics, Inc.

Issuer-level insider activity

Role
President & CEO, Director
Issuer ticker
SYRE on Nasdaq
Identity Names, identifiers, and filing context for this profile. 1 identity field
Entity type
Individual
Source evidence Original filing metadata and source links for verification. 1 source field
Source filing history
Open source filing history

No buys or sells have been reported by Anthony G. Quinn since 10 Jun 2025

Reported holdings for Anthony G. Quinn in Spyre Therapeutics, Inc.

Form 4 holding President & CEO, Director

Aeglea BioTherapeutics, Inc.

Security class
Common Stock
Shares / value
550,540
Estimated value
$390,883
Report date
16 Mar 2022
Price
$0.7100
Ownership
Direct
Form 4 holding President & CEO, Director

Aeglea BioTherapeutics, Inc.

Security class
Common Stock
Shares / value
266,295
Estimated value
$189,069
Report date
16 Mar 2022
Price
$0.7100
Ownership
By trusts

Transaction history for Anthony G. Quinn in Spyre Therapeutics, Inc.

Sym Class Transaction % SEC-reported value SEC-reported price Shares Shares after Date Ownership
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .